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Abstract
The U.S. Food and Drug Administration (FDA) cautions
health care providers and patients regarding the use of testosterone replacement therapy products for the aging process, including a decrease in muscle strength, muscle mass,
and lack of energy or sexual desire, due to an increased risk
of heart attacks and strokes. Testosterone replacement therapy products are indicated for genetic defects, chemotherapy
damage, or damage to the hypothalamus or pituitary gland,
where testosterone is produced. A patient and his team of
health care professionals must seriously consider the risks
and benefits when using these products for other indications.
Use of testosterone replacement therapy products for low
testosterone due to natural aging has been on the rise due to
disease state awareness, pharmaceutical marketing and media attention. Pharmacists can make a difference in patients'
lives by conducting patient education and counseling for
these products.
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Testosterone replacement therapy (TRT) has received recent
attention in the scientific community as the U.S. Food and
Drug Administration (FDA) has communicated that caution
should be advised when using testosterone products for the
aging process, including for symptoms such as declining
muscle mass, muscle strength and libido. In September 2014,
the FDA used input from an advisory committee of experts to
conclude that there may be an increased cardiovascular risk
with testosterone use.1 With a March 2015 update, the FDA
states that testosterone products are now required to include labels indicating increased risk of heart attacks and
strokes. Health care providers are encouraged to inform
their patients of these risks.t
Testosterone replacement therapy products are indicated in
male patients who have genetic defects causing lack of testosterone production by the testes, damage from chemotherapy to the testes or damage to the hypothalamus or pituitary
gland. However, many males who receive testosterone products have been diagnosed with idiopathic hypogonadism,
which is a low level of testosterone due to no other determined reason except for aging. Within the past six years,
there has been a significant increase in the use of TRT products; 1.3 million patients received TRT prescriptions in 2009
compared to 2.3 million in 2013, with 70 percent of those
patients between the ages of 40 and 64 years.2 The increase
in use of TRT may be due to confounding factors including
the rise in the baby boomer generation, pharmaceutical marketing or media attention for low testosterone. Moreover,
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with the use of TRT nearly doubling in recent years, ongoing
investigational research studying the potentially harmful,
long-term effects of TRT is invaluable. Patients obtain medical advice from numerous outlets, many of them unreliable.
Thus, it is important that health care professionals are aware
of current research to provide appropriate and trustworthy
clinical advice and counseling to all patients.
Hypogonadism and Testosterone Replacement Therapy
Recommendations
Hypogonadism is the manifestation of testosterone deficiency or infertility in males, the symptoms of which vary depending on age. Symptoms in males before puberty include
small testes, phallus and prostate, decreased growth of pubic
hair, delayed epiphyseal closure resulting in disproportionately long limbs, gynecomastia, high-pitched voice and loss of
testicular function. Older patients with lower levels of testosterone may experience fatigue, decreased libido, impotence,
decreased sperm production, loss of lean muscle mass, hot
flashes and osteoporosis. 3
Testosterone replacement therapy may be prescribed to patients with low testosterone levels to reduce the severity of
these symptoms and, improve the patient's overall quality of
life. Short-term studies have shown an increase in lean body
mass and production of blood cells and a decrease in lowdensity lipoprotein (LDL) levels in patients using hormone
replacement. Libido has also been shown to improve in older
men.3
The American Association of Clinical Endocrinologists
(AACE) and American College of Endocrinology protocol for
standardized production of clinical guidelines recommend
the use of testosterone replacement for the following indications:
• Management of congenital or acquired primary
hypogonadism resulting from orchiectomy (surgical
removal of one or both testes) or testicular failure.
• Management of congenital or acquired primary
hypogonadism resulting from idiopathic gonadotropin/gonadotropin-re\easing hormone deficiency or
from pituitary-hypothalamic injury caused by tumors,
trauma or radiation.
• Androgen deficiency and acquired immune deficiency
syndrome (AIDS) wasting in human immunodeficiency
virus (HIV)-infected men.
• Low serum testosterone concentrations (less than 300
ng/dL) in patients receiving long-term corticosteroid
therapy.
• Improvement of body composition, strength, bone
density, frailty, cognitive function, mood, sexual
function, quality of life and to induce secondary sex
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characteristics in men with symptomatic androgen deficiency when the benefits outweigh potential risks.4.s
The Endocrine Society has recommended that a patient be
diagnosed with androgen deficiency only when displaying
consistent symptoms of low serum testosterone levels diagnosed by measuring morning total testosterone levels by a
reliable assay. Measurement of total testosterone levels
should be repeated for confirmation. The panel of experts
disagreed on the exact level of serum testosterone. Some
panelists saw the benefits of treating patients with serum
testosterone levels of 280 to 300 ng/dL, which is the lower
limit of normal for a healthy adult male. Clinical trial data
indicates a level of 200 ng/dL or less would be appropriate
for diagnosis and initiation of replacement therapy. Goal testosterone levels, once replacement therapy has been initiated, should be mid-normal levels (normal range 300 to 1,050
ng/dL) and consistently monitored.6,7
The Endocrine Society has recommended against the use of
TRT in patients with breast or prostate cancer or a palpable
prostate nodule. It is also not recommended to use TRT in
patients with levels of prostate-specific antigen (PSA), a glycoprotein enzyme that can serve as a biomarker for prostate
disorders, above 4 ng/dL or in men at high risk for prostate
cancer.6 It is the general consensus of both the FDA and Endocrine Society that TRT should not be generally offered to
all older male patients with low testosterone levels.1.6 Before
testosterone therapy is recommended, physicians should
discuss the potential risks and benefits with their patients.6
Use of TRT for erectile dysfunction is currently not an FDA
labeled use in men with normal serum testosterone levels,
although it has been prescribed for this indication. 1.6 Because
men presenting with hypogonadism tend to have increased
likelihood of mood disturbances including depression, low
self-esteem and learning problems, it is recommended that
TRT be combined with psychiatric counseling for the most
beneficial results.3
Testosterone replacement therapy seems to have a positive
effect on patients' symptoms and quality of life in short-term
follow-up. However, research evaluating the long-term effects of TRT is scarce. Studies assessing the potential cardiovascular complications and cancerous associations with TRT
have shown conflicting results. Ongoing long-term research
and increased awareness of the potential risks will only help
improve patient care.3
Increased use ofTRT in Men and Performance Enhancement
Idiopathic hypogonadism associated with aging has been
shown to affect between 5 percent and 40 percent of males
between the ages of 40 and 79 years. Lower testosterone
levels manifest in ways that can deeply affect a patient's
quality of life, but may not warrant immediate action from a
physician. However, in recent years, there has been increased awareness of this disorder which has resulted in
increased prescribing for testosterone replacement. Largely
due to media attention and pharmaceutical marketing, patients have begun to seek treatment for hypogonadism. This
can be evidenced by the 500 percent increase in prescripSpring 2015 Volume 6, Issue 2
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tions since 1993.7 Most likely stemming from a desire to retain the level of wellness and physical activity one had at a
younger age, consumer spending on testosterone therapies
has exponentially increased. In 2011, $1.6 billion was spent
on TRT prescriptions, almost tripling what was spent in
2006.8
Also contributing to the surge of TRT prescriptions is use of
testosterone for enhancement of physique and increased
muscle mass used most significantly by athletes and bodybuilders. According to the New England Journal of Medicine,
androgen therapy for the purpose of performance enhancement began in the1940s and has since skyrocketed. Doses of
TRT for performance enhancement are 100 times larger than
those used for appropriate indications and require significant periods of time off therapy in order to allow the body to
recover from adverse reactions caused by such large doses.9
As the baby boomer generation ages and direct-to-consumer
advertising becomes more popular, TRT prescriptions are
projected to increase. Without readily available research of
long-term TRT or the proper awareness of potential complications of TRT, concern for patient safety should be of the
utmost importance.10
Risks Associated with Testosterone Replacement Therapy
It is currently agreed upon that there may be some long-term
risks involving TRT. The AACE published a comprehensive
report on treating men with hypogonadism, reporting on
TRT as a treatment option and the identification of potential
side effects that might accompany treatment.3 One potential
adverse event is cardiovascular morbidity. However, a consensus has not been reached as to how TRT and testosterone
levels in the aging male body affect cardiovascular health.
There is a large body of literature suggesting that testosterone therapy may increase the risk of certain adverse cardiovascular events, including nonfatal myocardial infarction
and stroke in older men (due to testosterone's tendency to
increase platelet aggregation), and in young men with
preexisting heart conditions.3,10,11
In 2010, Malkin and colleagues published a paper suggesting
that low serum testosterone (i.e., endogenous) levels correlate with increased mortality in men with coronary heart
disease.12 Other work by Malkin and his colleagues has
demonstrated that testosterone therapy improves functional
capacity and reduces symptom severity in men with moderate severity heart failure.13The important distinction to
make between the conflicting evidence is that low endogenous testosterone levels were related to adverse cardiovascular effects, whereas TRT, by definition, introduces exogenous
testosterone to the endocrine system. This does, however,
raise questions as to whether it is worth the risk to utilize
TRT as a treatment for hypogonadism in male patients with
preexisting cardiovascular risks.
In addition to the adverse effects that TRT may have on cardiovascular health, the AACE report also emphasizes the
need to evaluate elevated risks of prostate cancer that may
or may not be associated with TRT.3 It has already been es-
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tablished that patients with prostate cancer are not recommended to receive TRT. 3,4 However, it is less clear as to
whether there is a direct relationship between TRT and increased risk of prostate cancer in cancer-free patients at
baseline. A 2005 paper from the Brady Urological Institute at
Johns Hopkins Hospital showed a correlation between high
levels of free serum testosterone with higher incidences of
prostate cancer, leading the authors to directly call into question the safety of TRT as it relates to elevated risk of prostate
cancer.14 Information regarding adverse effects and formulation -specific adverse effects of TRT are presented below in
Table 1 and Table 2.

In the opposing camp, Rhoden and Morgentaler (2003)
concluded that TRT is not an ill-advised treatment option in
hypogonadic patients, even in those who have prostatic
intraepithelial neoplasia (PIN), a precancerous prostatic
lesion that often leads to the development of prostate
cancer.ls In a later 2010 study, Morgentaler and colleagues
further concluded that testosterone therapy in men with untreated prostate cancer was not associated with progression
of the disease in the first three to 12 months. They recommended that the discouraged use of testosterone therapy in
men with less severe prostate cancer or treated prostate cancer should be reconsidered. 14 Recently, TRT is being consid-

Potential Adverse Side Effects and Various Types of Testosterone Replacement Therapy.s
Table 1. General Testosterone Administration Adverse Effects.
Adverse events for which there is evidence of association
with testosterone administration

Erythrocytosis
Acne and oily skin
Detection of subclinical prostate cancer
Growth of metastatic prostate cancer
Reduced sperm production and fertility

Uncommon adverse events for which there is weak evidence
of association with testosterone administration

Gynecomastia
Male pattern balding (familial)
Growth of breast cancer
Induction or worsening of obstructive sleep apnea

Table 2. Formulations and Formulation Specific Adverse Effects.
Formulation

Specific Adverse Effects

Intramuscular injections of testosterone ethanate,
cypionate or undecanoate

Fluctuation in mood or libido
Pain at injection site
Excessive erythrocytosis (especially in older patients)
Coughing episodes immediately after the intramuscular
injection*

Transdermal patches

Frequent skin reactions at application site

Transdermal gel

Potential risk for testosterone transfer to partner or
another person who is in close contact (need to
remind patient to cover application sites with clothing
and to wash skin and hands with soap before having
skin-to-skin contact with another person)
Skin irritation

Buccal testosterone tablets

Alterations in taste
Irritation of gums

Pellet Implants

Infection, expulsion of pellet

Oral tablets

Effects on liver and cholesterol (methyltestosterone)t

*The mechanism of cough, which has been reported rarely after intramuscular injections of testosterone undecanoate and even more
rarely after testosterone enanthate and cypionate, is unknown, but it has been attributed to oil embolization.
tLiver toxicity has been reported mostly with oral 17-alpha alkylated androgens. The frequency of skin reactions is higher with the
testosterone patch than with the transdermal gels.
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ered in patients with hypogonadism associated with prostate
cancer comorbidities in some cases, although consistent
monitoring is strictly encouraged.15
Monitoring Parameters
Treatment monitoring is important to ensure the patient
safety remains at the center of all individualized therapy regimens. Testosterone and its byproducts stimulate the growth
of the prostate gland and seminal vesicles. While current research has failed to definitively prove a direct correlation
between TRT and increased PSA levels or abnormal prostate
growth, monitoring of these parameters is still essential. Follow-up appointments every three to four months is crucial
for all patients receiving TRT during the first year of therapy.13 Patients receiving injected testosterone should have
their serum testosterone measured at the midpoint between
injections; the level should be within a mid-normal range. 3

Digital rectal exams (DRE) are recommended every six to 12
months and PSA levels should be measured annually in older
males. If PSA levels are determined to be abnormally high
(greater than 4 ng/dL), TRT should be discontinued and the
patient may need to be referred for urologic consult. In patients concurrently receiving finasteride, further evaluation
may be warranted if PSA levels show a significant increase. 3
Because testosterone increases production of blood cells by
the bone marrow, hematocrit should also be routinely monitored every six to 12 months so that coagulation does not
result. TRT should be discontinued if hematocrit rises above
50 percent. Other side effects reported with testosterone
therapy include gynecomastia resulting from the chemical
change testosterone undergoes in the body to produce estrogen and an increased risk of alopecia. This should be considered when assessing the risk versus benefit analysis for each
patient.14
How Can Pharmacists Help?
As with any prescription, counseling from a pharmacist is
highly recommended. Considering the added risks of
hormone therapy, patient education of TRT is a necessity.
Testosterone therapy is available in a wide range of formulations including injection, transdermal patches and topical
gels, each with their own set of precautions and specific
directions for application. Successful and safe utilization of
therapy for each patient requires thorough comprehension
of their TRT prescriptions.

It is also important that a patient be equipped with all the
relevant information regarding the risks of initiating TRT at
the point of prescribing. Physicians should attempt to present accurate information to each patient, especially in a society where faulty information is only a click away, and help
the patients make the best possible decision in accordance
with their own individual health and wellness.
Conclusion
Testosterone therapies are a rapidly-growing option for aging men that will continue to expand with the aging of the
baby boomer generation, due to a higher incidence of hySpring 2015 Volume 6, Issue 2
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pogonadism in the aging population. Increased use of TRT
coupled with its high potential for abuse make counseling
and education an essential step for pharmacists at the time of
dispensing. The growing demand for testosterone replacement in conjunction with the FDA requirement to label the
increased risk of heart attacks and strokes on testosterone
products necessitates that health care providers utilize caution when prescribing these therapies and share their awareness of the potential risks and benefits associated with using
these products with patients.I
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